Johnson & Johnson

The anticipation is palpable… and building fast. We've had three reports on extremely effective upcoming coronavirus vaccines, and each report practically blows the last one out of the water.

First we heard preliminary reports that Pfizer and BioNTech's revolutionary messenger RNA (mRNA) coronavirus vaccine was 90% effective. That was great… until yesterday morning, when the biotechs got back in touch to say the real figure was something closer to 95%. And in the middle, we've heard from Moderna, which is reporting its mRNA vaccine is 94.5% effective.

Every time, stocks have taken off like a shot at the news; vaccines have helped push the Dow back above its February 2020 highs.

Here's the thing… setting aside the six vaccines The New York Times reports are in limited use in China and Russia – about which there are many unanswered questions – there are at least nine more coronavirus vaccines deep in phase 3, large-scale efficacy trials.

And there are no less than 55 more candidates in earlier, phase 1 and 2 trials. Some of these vaccine candidates won't advance, but others almost certainly will – two have already.

That all this has happened in less than a year is an "Apollo moonshot"-like scientific achievement. But that's also a whole lot of concentrated upside potential that could flood the markets and push stocks to almost unthinkable highs.

So I asked Money Morning Chief Investment Strategist Shah Gilani what it all means for us investors…